2 active not recruiting, 2 completed, 2 enrolling by invitation, 1 available. 6 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Active not recruiting 2, Enrolling by invitation 2, Completed 1, Recruiting 1 |
| Phase 2 | 3 | Completed 1, Enrolling by invitation 1, Terminated 1 |
Follow Pharvaris Netherlands B.V.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency Deucrictibant, Placebo - Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH) | Phase 3 | Recruiting | Pharvaris Netherlands B.V. | 48 | 2025-10-16 | 2026-09-21 |
| Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE Deucrictibant - Hereditary Angioedema (HAE) | Phase 3 | Enrolling by invitation | Pharvaris Netherlands B.V. | 170 | 2025-02-01 | 2026-09-22 |
| Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE Deucrictibant, Placebo - Hereditary Angioedema (HAE) | Phase 3 | Active not recruiting | Pharvaris Netherlands B.V. | 81 | 2024-12-01 | 2026-02-13 |
| Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema Deucrictibant, Placebo - Hereditary Angioedema, Hereditary Angioedema Type I | Phase 3 | Completed | Pharvaris Netherlands B.V. | 134 | 2024-02-26 | 2025-11-21 |
| Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor Icatibant, Placebo - Intradialytic Hypotension | Phase 3 | Active not recruiting | Vanderbilt University Medical Center | 26 | 2023-12-11 | 2026-10-22 |
| Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema deucrictibant - Hereditary Angioedema, Hereditary Angioedema Type I | Phase 2 / Phase 3 | Enrolling by invitation | Pharvaris Netherlands B.V. | 150 | 2022-12-28 | 2026-07-21 |
| Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II Deucrictibant low dose, Deucrictibant high dose, Placebo - Hereditary Angioedema, Hereditary Angioedema Type I | Phase 2 | Terminated | Pharvaris Netherlands B.V. | 34 | 2022-04-19 | 2026-08-17 |
| Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema Deucrictibant, Placebo - Hereditary Angioedema, Hereditary Angioedema Type I | Phase 2 | Completed | Pharvaris Netherlands B.V. | 74 | 2021-02-03 | 2025-12-17 |
| EAP for Deucrictibant Immediate-release Deucrictibant IR - Hereditary Angioedema | Available | Pharvaris Netherlands B.V. | 2026-08-12 |
Angioedemas, Hereditary (8) · Hereditary Angioedema Types I and II (4) · Angioedema (2) · Hereditary Angioedema Type III (2) · Acquired angioedema (1)
icatibant (1)
United States (8) · Bulgaria (7) · Canada (7) · Germany (7) · Italy (7) · Poland (7) · United Kingdom (7) · France (6) · Hungary (6) · Spain (6) · Austria (5) · Turkey (Türkiye) (5) · Argentina (4) · Australia (4) · Brazil (4)
Jorge L Gamboa, MD/PhD (1) · Marc Riedl, MD (1) · Marcus Maurer, Prof MD (1) · Peter Kotanko, MD, FASN (1) · Talat A Ikizler, MD (1)
PMID 41865746, PMID 41865747, PMID 42849489
2023 (1)